Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: Multi-center, Open-Label, Single-Arm Study of Yondelis (trabectedin) for Subjects With Locally Advanced or Metastic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment. Phase III ET743-SAR-3002

 


Multi-center, Open-Label, Single-Arm Study of Yondelis (trabectedin) for Subjects With Locally Advanced or Metastic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment. Phase III ET743-SAR-3002


Trial Focus

Sarcoma

Objective

         A clinical trial of the investigational drug Yondelis, administered by intravenous infusion.

IRB Protocol #

06-0026

Trial Status

OPEN

Principle Investigator

ANTHONY ELIAS

Sponsor

Johnson & Johnson Pharmaceutical R & D, LLC

Contact

MEGHAN HOULIHAN at (720)848-1156 or MEGHAN.HOULIHAN@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last approximately 4 months. A follow up period will consist of a clinic visit. // Eligibility criteria include but are not limited to patients 18 years or older with advanced soft tissue sarcoma.Eligibility criteria include but are not limited to patients 18 years or older with advanced soft tissue sarcoma.